CCDC130 Inhibitors

CCDC130 inhibitors encompass a variety of compounds that target different cellular pathways and processes in which CCDC130 is implicated. For example, mTOR inhibitors such as rapamycin can lead to the inhibition of CCDC130 by downregulating mTORC1 activity, which is a known regulator of ciliogenesis and autophagy. Since CCDC130 has roles in these processes, mTOR inhibition can result in decreased functional activity of CCDC130. Similarly, inhibitors of the PI3K/Akt pathway like LY294002 can have a downstream effect on CCDC130 activity by inhibiting processes that are essential for its role in ciliogenesis. In this way, targeting upstream regulators can be an indirect but effective strategy to modulate the function of CCDC130. Other compounds, such as perhexiline and 2-deoxy-D-glucose, impact cellular metabolism and energy status, which is crucial for energy-intensive processes like ciliogenesis. By altering these metabolic pathways, these inhibitors can lead to a reduction in CCDC130 activity as the cell prioritizes survival over specialized processes like ciliogenesis in the face of metabolic stress.